Market Cool On HUTCHMED (China) Limited's (LON:HCM) Revenues

With a median price-to-sales (or "P/S") ratio of close to 4.4x in the Pharmaceuticals industry in the United Kingdom, you could be forgiven for feeling indifferent about HUTCHMED (China) Limited's (LON:HCM) P/S ratio, which comes in at about the same. Although, it's not wise to simply ignore the P/S without explanation as investors may be disregarding a distinct opportunity or a costly mistake.

View our latest analysis for HUTCHMED (China)

How HUTCHMED (China) Has Been Performing

Recent times have been advantageous for HUTCHMED (China) as its revenues have been rising faster than most other companies. It might be that many expect the strong revenue performance to wane, which has kept the P/S ratio from rising. If you like the company, you'd be hoping this isn't the case so that you could potentially pick up some stock while it's not quite in favour.

Keen to find out how analysts think HUTCHMED (China)'s future stacks up against the industry? In that case, our free report is a great place to start.

How Is HUTCHMED (China)'s Revenue Growth Trending?

There's an inherent assumption that a company should be matching the industry for P/S ratios like HUTCHMED (China)'s to be considered reasonable.

If we review the last year of revenue growth, the company posted a terrific increase of 89%. Pleasingly, revenue has also lifted 262% in aggregate from three years ago, thanks to the last 12 months of growth. Therefore, it's fair to say the revenue growth recently has been superb for the company.

Shifting to the future, estimates from the analysts covering the company suggest revenue should grow by 10% per year over the next three years. With the industry only predicted to deliver 7.0% per year, the company is positioned for a stronger revenue result.

With this information, we find it interesting that HUTCHMED (China) is trading at a fairly similar P/S compared to the industry. It may be that most investors aren't convinced the company can achieve future growth expectations.

What We Can Learn From HUTCHMED (China)'s P/S?

We'd say the price-to-sales ratio's power isn't primarily as a valuation instrument but rather to gauge current investor sentiment and future expectations.

Despite enticing revenue growth figures that outpace the industry, HUTCHMED (China)'s P/S isn't quite what we'd expect. There could be some risks that the market is pricing in, which is preventing the P/S ratio from matching the positive outlook. At least the risk of a price drop looks to be subdued, but investors seem to think future revenue could see some volatility.

Many other vital risk factors can be found on the company's balance sheet. Take a look at our free balance sheet analysis for HUTCHMED (China) with six simple checks on some of these key factors.

If you're unsure about the strength of HUTCHMED (China)'s business, why not explore our interactive list of stocks with solid business fundamentals for some other companies you may have missed.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.